Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Cantor Fitzgerald
Chinese Patent Office
US Army

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019152

« Back to Dashboard

NDA 019152 describes CALAN SR, which is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. Additional details are available on the CALAN SR profile page.

The generic ingredient in CALAN SR is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Summary for 019152
Tradename:CALAN SR
Ingredient:verapamil hydrochloride
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 019152
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CALAN SR verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 019152 NDA G.D. Searle LLC Division of Pfizer Inc 0025-1891 0025-1891-31 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0025-1891-31)
CALAN SR verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 019152 NDA G.D. Searle LLC Division of Pfizer Inc 0025-1891 0025-1891-51 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0025-1891-51)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength240MG
Approval Date:Dec 16, 1986TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength180MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Dec 15, 1989TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength120MG
Approval Date:Mar 6, 1991TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Johnson and Johnson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.